期刊文献+

硬皮病动物模型建模药物最适浓度探讨 被引量:4

Optimal drug concentration for scleroderma mouse model
下载PDF
导出
摘要 目的探讨用博来霉素(BLM)制作硬皮病动物模型的最适浓度。方法将24只BALB/C小鼠随机平均分为3个实验组和1个对照组,各实验组小鼠分别皮下注射200、700和1 000μg/ml浓度的BLM,对照组小鼠皮下注射等量的磷酸盐缓冲液(PBS),注射4周后处死小鼠,取注射部位皮肤行苏木精-伊红染色法(HE)染色、Masson染色、真皮羟脯氨酸含量检测及真皮厚度检测。结果 700和1 000μg/ml浓度的BLM成功建模,但1 000μg/ml的浓度可导致小鼠皮肤浅表溃疡。结论硬皮病动物模型成功与否与BLM药物浓度高低关系密切,700μg/ml博莱霉素浓度具有较好的建模效果,且不会出现皮肤溃疡的副作用。 Objective To analyze the optimal concentration of Bleomycin for scleroderma mouse model.Methods Twenty-four BALB/c mice were divided into 4 groups including 3 experimental groups and 1 control group. The mice of the experimental groups were injected with 200, 700 and 1,000 μg/ml Bleomycin respectively and those in the control group were injected with PBS. The staining for HE and Masson, and detection for dermis hydroxyproline content and dermis thickness were executed after the extraction of injective-site skin about 4 weeks later. Results Scleroderma mouse model was successfully established at the 700 and 1,000 μg/ml concentration of Bleomycin, but the skin ulcer of injective site occured in the experimental group of 1,000 μg/ml concentration. Conclusions There is a close relationship between establishment of scleroderma mouse model and drug concentration. The 700 μg/ml concentration of Bleomeycin has a good molding effect, which does not have the side effect like skin ulcer.
出处 《中国现代医学杂志》 CAS 北大核心 2016年第1期1-4,共4页 China Journal of Modern Medicine
基金 国家自然科学基金(No:81460473) 广西自然科学基金(No:2012NSFAA053133)
关键词 硬皮病 博来霉素 动物模型 最适浓度 scleroderma Bleomycin animal model optimal concentration
  • 相关文献

参考文献12

  • 1Young A, Khanna D. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014[J]. Curr Opin Rheumatol, 2015, 27(3): 241-248.
  • 2Koca SS, Ozgen M, Sarikava M, et al. Ghrelin prevents the development of dermal fibrosis in bleomycin-induced scleroderma[J]. Clin Exp Dermatal, 2014, 39(2): 176-181.
  • 3Maurer B, Distler A, Suliman YA, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis[J]. Ann Rheum Dis, 2014, 73(10): 1880-1887.
  • 4Demir T, Turkbeyler I, Kaplan DS, et al. Effectiveness of palosuran in bleomycin-induced experimental scleroderma[J]. Inflammation, 2013, 36(1): 75-79.
  • 5Ek WE, Sahlqvist AS, Croo KS, et al. Mapping QLT affecting a systemic sclerosis-like disorder in a cross between UCD-200 and red jungle foul chicken[J]. Dev Comp Immunol, 2012, 38(2): 352-359.
  • 6Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma[J]. Nature, 2013, 503(7474): 126-130.
  • 7Toshiyuki Y, Kiyoshi N. Animal model of sclerotic skin. V: increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma[J]. Clin Immunol, 2002, 102(1): 77-83.
  • 8Juniantito V, Izawa T, Yuasa T, et al. Immunophenotypical characterization of macrophages in rat bleomycin-induced scleroderma[J]. Vet Pathol, 2013, 50(1): 76-85.
  • 9Avouac J, Furnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis[J]. Arthritis Rheum, 2011, 63(3): 800-809.
  • 10李海涛,杨蓉娅,朱晓丹,樊昕,王文岭.UVA_1对硬皮病小鼠模型影响的实验观察[J].中国麻风皮肤病杂志,2008,24(1):20-22. 被引量:2

二级参考文献29

  • 1朱鹭冰,李明.博来霉素诱导硬皮病小鼠模型及其抗体测定的初步研究[J].中华皮肤科杂志,2003,36(9):496-498. 被引量:15
  • 2Yamamoto T,Takagawa S,Katayama I,et al.Animal model of sclerotic skin.Ⅰ.Local injections of bleomycin induce sclerotic skin mimicking scleroderma[J].J Invest Dermatol,1999,112 (4):456-462.
  • 3Yamamoto T,Kuroda M,Nishioka K.Animal model of sclerotic skin.Ⅲ:Histopathological comparison of bleomycin-induced scleroderma in various mice strains[J].Arch Dermatol Res,2000,292 (11):535 -541.
  • 4Yamamoto T,Nishioka K.Role of monocyte chemoattractant protein-1 and its receptor,CCR-2,in the pathogenesis of bleomycininduced scleroderma[J].J Invest Dermatol,2003,121 (3):510-516.
  • 5Sambo P,Jannino L,Candela M,et al.Monocytes of patients with systemic sclerosis (scleroderma) spontaneously releases in vitro increased amounts of superoxide anion[J].J Invest Dermatol,1999,112 (1):78-84.
  • 6Yamamoto T,Takagawa S,Nishioka K.Mast cell independent increase of type Ⅰ collagen expression in experimental scleroderma induced by bleomycin[J].Arch Dermatol Res,2001,293(10):532-536.
  • 7Yamamoto T,Takahashi Y,Takagawa S,et al.Animal model sclerotic skin.Ⅱ.Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W (V) mice[J].J Rheumatol,1999,26 (12):2628-2634.
  • 8Roberts AB,Sporn MB.The transforming growth factors[A].In:Sporn M B,Roberts A B,eds.Handbook of Experimental Pharmacology[M].Peptide Growth Factors and Their Receptors,[M] Vol.95.New York:Springer-Verlag,1990:419-472.
  • 9Van Obberghen-Schilling E,Roche NS,Flanders KC,et al.Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells[J].J Biol Chem,1988,263 (16):7741 -7746.
  • 10Roberts AB,Sporn MB,Assoian RK,et al.Transforming growth factor type beta:rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro[J].Proc Natl Acad Sci USA,1986,83 (12):4167-4171.

共引文献1

同被引文献30

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部